| Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro M Olsson, P Larsson, J Johansson, VR Sah, TZ Parris Frontiers in Cell and Developmental Biology 11, 1237673, 2023 | 4 | 2023 |
| Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer P Larsson, D Pettersson, M Olsson, S Sarathchandra, A Abramsson, ... Cell Death Discovery 10 (1), 57, 2024 | 2 | 2024 |
| Integrated transcriptomics-and structure-based drug repositioning identifies drugs with proteasome inhibitor properties P Larsson, MC De Rosa, B Righino, M Olsson, BI Florea, ... Scientific Reports 14 (1), 18772, 2024 | 1 | 2024 |
| Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers P Larsson, M Olsson, S Sarathchandra, A Fäldt Beding, ... Scientific Reports 14 (1), 18576, 2024 | | 2024 |
| Abstract P4-08-17: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer P Larsson, D Pettersson, M Olsson, E Forssell-Aronsson, A Kovács, ... Cancer Research 83 (5_Supplement), P4-08-17-P4-08-17, 2023 | | 2023 |
